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Loss-of-function mutations in genes for heme biosynthetic en-
zymes can give rise to congenital porphyrias, eight forms of which
have been described. The genetic penetrance of the porphyrias is
clinically variable, underscoring the role of additional causative,
contributing, and modifier genes. We previously discovered that
the mitochondrial AAA+ unfoldase ClpX promotes heme biosyn-
thesis by activation of δ-aminolevulinate synthase (ALAS), which
catalyzes the first step of heme synthesis. CLPX has also been re-
ported to mediate heme-induced turnover of ALAS. Here we report
a dominant mutation in the ATPase active site of human CLPX,
p.Gly298Asp, that results in pathological accumulation of the heme
biosynthesis intermediate protoporphyrin IX (PPIX). Amassing of
PPIX in erythroid cells promotes erythropoietic protoporphyria
(EPP) in the affected family. The mutation in CLPX inactivates its
ATPase activity, resulting in coassembly of mutant and WT protomers
to form an enzyme with reduced activity. The presence of low-activity
CLPX increases the posttranslational stability of ALAS, causing in-
creased ALAS protein and ALA levels, leading to abnormal accu-
mulation of PPIX. Our results thus identify an additional molecular
mechanism underlying the development of EPP and further our
understanding of the multiple mechanisms by which CLPX controls
heme metabolism.
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Porphyrias result from disorders of heme synthesis and areassociated with mutations in numerous heme synthetic en-
zymes (1). The genetic penetrance of porphyria-causing alleles is
variable, however (1–3), often due to the presence of diverse
environmental factors and the existence of modifier genes. In
addition, some patients with porphyria who suffer from cutane-
ous photosensitivity and abnormal liver function have illnesses of
unknown etiology, highlighting our incomplete understanding of
this complex condition.
Erythropoietic protoporphyria (EPP) is a disorder character-
ized by the pathological accumulation of a late heme bio-
synthetic intermediate, protoporphyrin IX (PPIX), in erythroid
cells. Approximately 90% of patients with EPP carry a partial
deficiency in FECH (EC 4.99.1.1, OMIM 177000), the gene for
the mitochondrial enzyme ferrochelatase, which catalyzes the
insertion of iron into PPIX for the final step in heme production.
In most cases, EPP is due to cosegregation of a heterogeneous,
family-specific deleterious FECH allele in compound heterozy-
gosity with the common, low-expression, c.315–48C FECH allele,
which affects the use of a cryptic splice-acceptor site in FECH
pre-mRNA (4–6). A second, less common class of EPP results
from gain-of-function mutations in ALAS2, the erythroid-specific
gene for δ-aminolevulinate synthase (ALAS; EC 2.3.1.37, OMIM
300752), which catalyzes the initial step in heme biosynthesis.
These dominant, gain-of-function ALAS2 alleles increase ALA
production, which triggers the accumulation of downstream heme
precursors, especially PPIX. The proportion of patients with EPP
with an ALAS2mutation is <5% in Europe (4, 5) and <10% in the
United States (2). Importantly, genetic analysis fails to detect
FECH and ALAS2 mutations in 1–5% of families with a member
with EPP (which are mostly homozygous for the WT FECH
c.315–48T allele), suggesting involvement of loci other than
FECH and ALAS2 in this important metabolic illness (3, 7).
Significance
Although heme synthesis is ubiquitous, specific regulatory
mechanisms couple heme production to cellular demand and
environmental conditions. The importance of these regulatory
mechanisms is highlighted by clinical variability in porphyrias
caused by loss-of-function mutations in heme synthesis en-
zymes. Heme synthesis is also controlled by the mitochondrial
AAA+ unfoldase ClpX, which participates in both heme-
dependent degradation of δ-aminolevulinate synthase (ALAS)
and ALAS activation. This study reports a human familial muta-
tion in CLPX that contributes to erythropoietic protoporphyria
(EPP) by partially inactivating CLPX. Reduced CLPX activity in-
creases ALAS post-translational stability, causing pathological
accumulation of protoporphyrin IX (PPIX) in human patients. Our
results thus identify an additional gene that promotes PPIX
overproduction and EPP and highlight the complex gene net-
work contributing to disorders of heme metabolism.
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Here, we report the identification of a third mechanism un-
derlying EPP in an affected family. This EPP is promoted by a
mutation in CLPX, which encodes an AAA+ (ATPases associ-
ated with various cellular activities) protein unfoldase. ClpX is
widely conserved among bacteria and in the eukaryotic mito-
chondrion. ClpX works as a ring-shaped homohexamer and is
best understood in its function in a proteasome-like complex
with the peptidase ClpP (i.e., the ClpXP ATP-dependent pro-
tease). For well-studied examples of ClpXP substrates in bacteria,
ClpX recognizes specific short sequence motifs in the substrate
protein. ClpX unfolds the tertiary structure of substrate protein by
ATP-powered polypeptide translocation through its central pore
and then presents this unfolded sequence directly into the ClpP
proteolytic chamber (reviewed in ref. 8). Recently, ClpX has been
identified as a modulator of heme biosynthesis by activating ALAS
(9), and also has been observed to mediate the turnover of ALAS
under heme-replete conditions; this turnover requires a heme-
binding motif in ALAS (10).
Here, we report the identification and analysis of a dominant
heterozygous mutation that disables the ATPase activity of CLPX,
causing accumulation of PPIX in red blood cells and promoting
the development of EPP symptoms. Our experiments demonstrate
how this impaired CLPX activity causes deleterious effects in
heme metabolism, organismal physiology, and human health.
Results
An EPP-Affected Family Carries a Dominant CLPX Allele.We recently
identified a family from Northern France in which the proband
suffers from EPP of unknown etiology (Fig. 1A). The proband,
an 18-y-old Caucasian female, was referred to the French Center
of Porphyria because of early-onset (9 mo) acute photosensitivity,
characterized by painful phototoxic reactions and elevated levels
of free and zinc-chelated erythroid PPIX, phenotypes suggestive of
EPP (Table 1). At the time of diagnosis, she also presented with a
microcytic iron-deficiency anemia (Table 1). Her ferrochelatase
(FECH) activity was normal. Furthermore, she did not carry any
of the known gain-of-function mutations in the ALAS2 gene that
lead to EPP. No point mutations or large FECH gene deletions on
chromosome 18 (3), where the FECH gene is located, were iden-
tified by linkage and comparative genomic hybridization array
analysis (SI Appendix, Fig. S1). Moreover, she did not harbor the
c.315–48C FECH low-expressed allele (4). Taken together, these
data demonstrate that the proband has an unusual form of EPP
(Table 1). Among the proband’s family members, her father (II.4)
and uncle (II.2) also presented with free and zinc-PPIX accumula-
tion in erythrocytes and associated mild photosensitivity, but without
the complete clinical symptoms of EPP (Fig. 1A and Table 1).
After linkage analysis and exclusion of candidate genes (SI
Appendix, Table S1), whole-exome sequencing revealed that the
proband (III.2) carried a single nucleotide substitution (g.27511
G > A) at the exon 7 splice junction border in one of her two
CLPX alleles (Fig. 1B). This mutation was not present in
126,216 control reference exomes queried in the genome ag-
gregation database (gnomad.broadinstitute.org), suggesting
that it is not a common human polymorphism. To establish the
inheritance pattern of this mutation, we performed Sanger
sequencing of gDNA obtained from whole blood of the proband’s
relatives and collected clinical data from these family members.
Among nuclear family members, only the proband’s father (II.4)
and uncle (II.2) harbored the identical heterozygous CLPX muta-
tion (Fig. 1A). Thus, the G > A transition in CLPX cDNA was fully
segregated with the PPIX accumulation and was inherited in a
pattern consistent with Mendelian dominance. The pre-mRNA
from the mutant allele was normally spliced (Fig. 1C), and
the mutation was predicted to encode the single amino acid
p.Gly298Asp substitution in the mature CLPX protein (CLPXGD).
Thus, we propose that this CLPX mutation increases PPIX
production with incomplete penetrance for full EPP; disease
progression and severity are likely influenced by environmental
conditions and/or genetic modifiers. Consequently, we went on
to explore the molecular mechanism by which this CLPX mu-
tation alters heme metabolism and contributes to EPP.
CLPXGD Has a Defective ATPase Active Site. Human CLPX glycine
298 is a highly conserved residue in the Walker A motif (Fig.
2A). This motif forms part of the ATP-binding pocket and par-
ticipates in the positioning and hydrolysis of ATP (reviewed in
ref. 8). The G298D mutation is predicted to prevent ATP
binding by steric occlusion or distortion of the active site (Fig.
2B); thus, we sought to determine whether the CLPX G298D
mutation in our pedigree caused EPP by disrupting the regula-
tory function(s) of CLPX on heme synthesis. To determine the
consequence of the G298D mutation on CLPX activity, we as-
sayed ATPase activity of wild-type (WT) murine CLPX and a
G298D CLPX variant (CLPXGD) in vitro. CLPXGD lacked de-
tectable ATPase activity and partially suppressed the ATPase
of WT CLPX protomers (Fig. 2C), suggesting that the dominant-
negative phenotype of the mutant allele could be caused by
Fig. 1. Sequencing identifies mutations in CLPX. (A) Mendelian dominant
inheritance segregation of PPIX overproduction was observed in the pro-
band’s family. The proband is indicated by an arrow. (B) Sequencing revealed a
single nucleotide substitution in CLPX (g.27511 G > A) in genomic DNA from
the proband (III.2). (C) Sequencing of cDNA revealed a single nucleotide sub-
stitution (c.1102 G > A) in the proband, but not in her mother (II.5), resulting in
a p.Gly298Asp missense mutation (CLPXGD). CLPXGD mRNA is normally spliced.
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heterooligomerization of WT and mutant CLPX subunits. Sup-
pression of WT CLPX ATPase activity by CLPXGD plateaued at
a ∼30% reduction in activity, indicating that WT CLPX proto-
mers within any heterooligomers retain partial activity.
CLPXGD Increases ALAS and PPIX Levels in Vivo. To determine
whether CLPXGD could induce erythropoietic porphyria, we
transiently expressed FLAG-tagged CLPX and CLPXGD in
HEK293T cells (Fig. 3A). HEK293T cells that expressed CLPXGD
contained ∼1.5-fold more PPIX than control or CLPX-expressing
cells (Fig. 3B). Because CLPX modulates ALAS activity (9, 10),
which in turn can alter downstream PPIX levels, we analyzed
ALAS activity in CLPX-expressing cells. In HEK293T fibroblasts,
expression of CLPX decreased endogenous ALAS1 activity (Fig.
3C), and this CLPX effect also lowered ALAS1 protein levels
(Fig. 3A). In contrast, the expression of CLPXGD resulted in in-
creased activity of ALAS1 (Fig. 3C) and a parallel increase in the
level of ALAS1 protein (Fig. 3A). Furthermore, consistent with
the findings reported by Kubota et al. (10), CRISPR-mediated
disruption of CLPX in K562 cells also caused an increase in
ALAS1 protein levels (SI Appendix, Fig. S2).
Expression of CLPXGD in Friend mouse erythroleukemia (MEL)
cells (Fig. 3D) similarly increased PPIX production (Fig. 3E) and
increased ALAS2 activity (Fig. 3F). Likewise, we observed that the
expression of CLPXGD increased ALAS2 protein levels, whereas
expression of CLPX decreased ALAS2 levels (Fig. 3D). Interest-
ingly, the decrease in ALAS2 protein caused by CLPXGD expression
did not change the total ALAS activity measured (Fig. 3F).
To determine whether CLPXGD similarly increased ALAS
activity in an animal model, we injected equal amounts of cRNA
encoding FLAG-tagged CLPX and CLPXGD into zebrafish
embryos. The injected CLPX and CLPXGD cRNA was efficiently
translated into CLPX protein (Fig. 3G). CLPXGD expression
caused an approximately twofold increase in ALAS activity (Fig.
3H), consistent with cell culture data.
We observed similar increases in ALAS protein levels and ac-
tivity in patient-derived cells as in CLPXGD-expressing cell and
animal models. ALAS1 levels (Fig. 4A) and activity (Table 2) were
elevated, as demonstrated by accumulation of the ALA metabolite
in EBV-immortalized lymphoblastoid cells obtained fromCLPXWT/GD
individuals. Modestly increased ALAS2 levels were also found in
erythroid cells obtained from differentiation of primary CD34+
hematopoietic stem cells from the index cases (Fig. 4B). Taken
together, our data demonstrate that expression of CLPXGD in cell
cultures and zebrafish phenocopies the CLPXGD effect in patient
cells, causing increased ALAS protein, higher ALA levels, and thus
accumulation of PPIX, the biochemical hallmark of EPP.
CLPXGD Slows ALAS Degradation in Vivo.An attractive hypothesis to
explain how CLPXGD causes PPIX accumulation is that the re-
duced activity of mixed hexamers of WT CLPX and CLPXGD
reduces the rate of CLPX-dependent degradation of both
ALAS1 (10) and ALAS2. Thus, we assessed whether CLPXGD
increased ALAS activity by increasing the stability of the ALAS
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Fig. 2. The CLPXGDmutation compromises the ATPase active site structure and
activity. (A) The CLPXGD mutation occurs in the highly conserved Walker A
ATPase motif. (B) Rendering of a nucleotide-binding pocket of ClpX (light gray)
with the Walker A motif (blue-gray) and the residue corresponding to H. sa-
piens CLPX Gly298 (salmon). Coordinates are from a structure of E. coli ClpX6
bound to ADP (PDB ID code 3HWS) (38). The dotted sphere represents the
maximum extension of an aspartate side chain from this position (3.72 Å). ADP
atoms are colored using the standard scheme, and side chain residues that form
hydrogen bonds with ADP are also shown. (C) ATPase activity of CLPX, CLPXGD,
and mixtures thereof. ATPase activity of 0.15 μM (hexamer concentration) CLPX
(WT), 0.15 μM CLPXGD (GD), or 0.15 μM CLPX plus 0.15, 0.3, or 0.75 μM CLPXGD
(WT + GD) is displayed. Activity is calculated relative to the concentration ofWT
CLPX in each condition (ATP per minute per WT CLPX6). Mean values ± SD are
plotted; n ≥ 3 biological replicates. *Reduced activity, P ≤ 0.005, Student’s t test.
Table 1. Biochemical data in affected subjects of the EPP family under study
Heme- and iron-related biochemical markers Reference* II.2 II.4 III.2
Total porphyrins in plasma, nmol/L <20 52 64 936
Erythroid PPIX, μmol/L RBC <1.9 26.7 30.4 140.9
Free PPIX, % <28 38 33 71
ZnPPIX, % >72 62 67 29
FECH activity, nmol/mg protein/h >3.5 4.5 4.4 3.6
Hemoglobin, g/dL 12–16 15.9 15.5 11.5
Iron, μmol/L 12–26 20 25 4
Transferrin saturation, % 20–45 32 31 5
Soluble transferrin receptor, mg/L 0.76–1.76 1.25 1.41 3.95
Ferritin, μg/L 15–250 (males) 171 196 5
8–150 (females)
All three individuals carrying one copy of the CLPXGD allele had significantly elevated total porphyrin, ery-
throid protoporphyrin, and free PPIX levels. Their FECH activities were normal. The proband (III.2) exhibited
symptoms of iron deficiency, with decreased iron, transferrin saturation, and ferritin levels, but this phenotype
did not cosegregate with the mutation.
*Reference values obtained from Ducamp et al. (14).
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proteins. We monitored the rate of ALAS1 and ALAS2 turnover in
cultured cells by Western blot analysis following inhibition of pro-
tein synthesis. In brief, we treated CLPX- or CLPXGD-expressing
HEK293T cells with cycloheximide (CHX) to inhibit de novo
translation (11–15), and monitored the decrease in ALAS1 or
ALAS2 protein over several hours by Western blot analysis.
ALAS1 degradation was slow specifically in cells expressing
CLPXGD (Fig. 4 C and D, Left). Interestingly, CLPXGD itself
was less stable than CLPX (Fig. 4 C and D, Right). ALAS2 deg-
radation was also decreased by expression of CLPXGD in dif-
ferentiating MEL cells (Fig. 4 E and F). Therefore, impaired
CLPX-dependent turnover of ALAS could explain the alterations
in both housekeeping and erythroid-specific heme synthesis
caused by the presence of heterozygous CLPXGD and CLPXWT
alleles.
Assembly of CLPX-CLPXGD Heteromeric CLPX Unfoldase and CLPXP
Protease. Previous work with Escherichia coli and human homo-
logs of ClpX and ClpP has demonstrated that ATP binding
stabilizes ClpX hexamers and is essential for ClpXP complex
formation (16–18). Given the effect of the G298D mutation on
the ATPase active site of ClpX, we believed it important to
Fig. 3. Expression of CLPXGD causes increased ALAS activity and increased PPIX. (A) Western blot analysis of mitochondrial lysates from HEK293T cells expressing
C-terminal FLAG-tagged CLPX or CLPXGD. (B) HPLC analysis of PPIX levels in HEK293T cells. (C) HPLC analysis of ALAS1 activity in HEK293T cells. (D) Western blot
analysis of MEL cells stably expressing C-terminal FLAG-tagged CLPX or CLPXGD. (E) HPLC analysis of PPIX levels in MEL cells. (F) HPLC analysis of ALAS2 activity (ALA
production) in MEL cells. (G) Western blot analysis of FLAG immunoprecipitation from lysates from uninjected and either CLPX-FLAG or CLPX-FLAGGD cRNA-injected
zebrafish embryos. (H) ALAS activity was assayed by HPLC from zebrafish embryos described in G. Mean values ± SEM are plotted; n > 3. *P < 0.05, Student’s t test.
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directly test the ability of CLPXGD to coassemble with WT CLPX
and with CLPP. Thus, we tested complex formation among these
purified protein variants. We found that the interaction of
CLPXGD with WT CLPX protomers was not substantially per-
turbed, as assessed by coimmunoprecipitation (co-IP) (Fig. 5A).
On analysis of CLPX-CLPP complex formation by CLPP pull-
down, WT CLPX was pulled down by CLPP in at ATP-dependent
manner, whereas CLPXGD was not pulled down by CLPP (Fig.
5B), as predicted because of its defective ATP-binding site. In an
equimolar mixture of CLPXGD and WT CLPX, however, both
CLPX variants coisolated with CLPP, but the total amount of
CLPX recovered was reduced to half of that recovered from the
WT CLPX-only condition. (Fig. 5B). These findings indicate that
mixed hexamers composed of WT and G298D CLPX interact
more weakly with CLPP than fully WT CLPX hexamers. There-
fore, along with reducing the ATPase activity of CLPX in the cell,
CLPXGD likely also reduces the abundance and degradation ac-
tivity of CLPXP complexes in vivo. If CLPXP directly degrades
the ALAS proteins, then this weakened CLPX-CLPP interaction
would be expected to contribute to the reduced ALAS1 and
ALAS2 turnover that we observe.
Discussion
Previous work has shown that ClpX activates ALAS by acc-
elerating incorporation of the essential ALAS cofactor, pyridoxal
5′-phosphate (PLP) (9). Knockdown of one of two ClpX homo-
logs in zebrafish, clpxa, caused an erythropoietic anemia that was
chemically complemented by the addition of ALA, indicating that
this anemia was due to reduced ALAS activity (9). Furthermore,
in this previous study, the CLPXP proteolytic complex was not
observed to degrade ALAS2 in vitro. The data reported here and
by Kubota et al. (10) suggest that additional factors, such as
autoregulatory free heme or collaboration with the Lon protease
(19), may be required for CLPX-mediated degradation of ALAS.
Based on our present results, we suggest a model that inte-
grates both mechanisms by which ClpX modulates ALAS activ-
ity, acceleration of PLP cofactor incorporation (activation), and
promotion of ALAS protein turnover (degradation) (Fig. 5C).
The balance of these mechanisms in vivo determines whether
stimulation or suppression of ALAS activity by CLPX is ob-
served. When CLPX is absent or expressed at only a low level,
both ALAS activation and degradation are strongly blocked,
causing an accumulation of ALAS with decreased enzymatic
activity and thus reduced ALA synthesis, causing anemia (Fig.
5C, Right). In the present study, CLPXWT/GD heterozygous in-
dividuals contain CLPXWT/GD heteromeric complexes with re-
duced ATPase activity and weakened interaction with CLPP.
The resulting reduction in ALAS degradation has a stronger
phenotypic consequence than possible decreased activation,
likely due in part to the weaker interaction of CLPXWT/GD
heterohexamers with the CLPP peptidase, resulting in a net in-
crease in ALA and PPIX (Fig. 5C, Middle). Furthermore, it is
well established with bacterial ClpXP that the unfolding of some
protein substrates requires much more ATP and a higher ClpX-
ATPase rate compared with other proteins, and the differences
depend on the specific structure of the substrate protein (reviewed
in ref. 20). The mixed CLPXWT/GD enzyme may be more defective
in the complete ALAS unfolding required for degradation than in
the limited unfolding that we proposed is required for activation
(9). Thus, when cells contain CLPXWT/GD heterohexamers, active,
intact ALAS accumulates. Cellular FECH activity and iron levels
are insufficient to convert the resulting excess PPIX to heme,
causing cells to accumulate free and zinc-PPIX and leading to
symptoms of porphyria.
Table 2. ALA metabolite levels (arbitrary units/g protein) in
lymphoblastoid cells obtained from CLPXWT/WT and CLPXWT/GD
individuals
CLPXWT/WT CLPXWT/GD
III.1 III.3 II.2 II.4 III.2
14.9 20.6 37.1 23.8 43.9
CLPXWT/GD individuals exhibit elevated levels of the ALA metabolite.
Fig. 4. Expression of CLPXGD mutant stabilizes ALAS protein. (A) Western
blot analysis of immortalized lymphoblastoid cells obtained from the proband
and her family members (Fig. 1A) showed increased levels of ALAS1 protein in
individuals carrying a CLPXGD allele (II.4, III.2, and II.2) compared with un-
affected family members (III.3 and III.1). (B) Western blot analysis of patient-
derived primary CD34+ hematopoietic stem cells differentiated to erythroid
cells. (C) CHX block of protein translation in HEK293 cells (cells as described in
Fig. 3A), followed by Western blot analysis of mitochondrial lysates collected
after treatment. (D, Left) Quantification of ALAS1 degradation after CHX
treatment. Both bands, corresponding to the precursor (upper band) and
mature (lower band) forms of ALAS1 were quantified. Quantification of CLPX
and CLPXGD degradation after CHX treatment. Both proteins were normalized
to HSP60 expression (n = 3). (E) Western blot analysis of time course following
CHX treatment in MEL cells expressing CLPX or CLPXGD. (F) Quantification of
ALAS2 degradation in E. ALAS2 was normalized to HSP60 expression. Mean
values ± SEM are plotted; n > 3. *P < 0.05, Student’s t test.
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The pedigree of the proband’s family clearly demonstrates the
dominant coinheritance of PPIX accumulation with the CLPXGD
allele through vertical transmission over two generations (Fig.1
and SI Appendix, Fig. S3). Human dominantly inherited diseases
are often characterized by incomplete penetrance and variable
presentation of disease symptoms, usually due to differences in
the influence of environmental factors and/or modifier genes on
different individuals. Our data suggest that the human dominant
CLPX disorder behaves in this manner, as observed for the
previously reported dominant porphyrias (1). Thus, we have
uncovered a new molecular basis for EPP, a defect in the AAA+
unfoldase CLPX that results in aberrant control of the key heme
synthetic enzyme ALAS.
Given the contribution of ClpX and ClpXP to essential organ-
ismal processes such as heme synthesis (9, 10) and mitochondrial
respiration (21, 22), it is likely that CLPX mutations contribute
to additional mitochondriopathies and metabolic disorders. Caus-
ative recessive mutations in CLPP have been identified in
Perrault syndrome (23, 24). Because no unfoldase-independent
role of ClpP is known or predicted, CLPX activity is likely re-
quired for the CLPP function(s) that are perturbed in Perrault
syndrome. CLPX mutations also could contribute to sideroblastic
anemia by slowing PLP incorporation into ALAS2, phenocopy-
ing XLPP caused by ALAS2 mutations that inhibit PLP binding
(25–28). Treatment with large doses of vitamin B6 (to yield PLP)
might bypass a deficiency in CLPX-stimulated PLP incorporation
into ALAS2 in a manner analogous to treatment of patients with
XLPP with B6-responsive ALAS2 mutations. Because the genetic
variant of EPP reported here shares more similarities with
ALAS2-based EPP (XLPP) than with FECH-based EPP, it could
be helpful to treat patients with CLPX-based EPP with supple-
mental iron to convert excess PPIX to heme, as has been bene-
ficial for patients with XLPP with a normal FECH gene (3, 29).
The incomplete EPP penetrance and variable clinical symptoms
observed among the CLPXGD-carrying individuals may be based
in environmental factors. In EPP, whether iron therapy is ef-
fective or might even sometimes worsen the disease is a matter
of debate (30, 31); however, recent work suggests that iron status
can modulate the phenotype both in congenital erythropoietic
porphyria (32) and in XLPP (3, 5, 29). Therefore, we speculate
that the iron deficiency of the index CLPXGD patient may result
from an independent pathological process that contributes to the
penetrance of EPP. It is our hope that further understanding of
the complex network of enzyme and cofactor interactions con-
trolling heme synthesis will continue to contribute ideas for
therapeutic strategies to treat diseases caused by aberrant reg-
ulation of heme metabolism.
Materials and Methods
Human and Vertebrate Animal Study Approval. The study was approved by
local Ethics Committees in accordance with the ethical principles for medical
research involving human subjects and its subsequent amendments of the
Declaration of Helsinki (R162-16–7 and 145–15-4, French ethical agreement).
All family members provided written informed consent, and the European
Union Institutional Review Board at INSERM approved the protocols. Ver-
tebrate animal studies were performed in compliance with Institutional
Animal Care and Use Committee protocols at Boston Children’s Hospital,
Brigham & Women’s Hospital, and MIT.
Biochemical Analysis. The diagnosis of EPP was based on biochemical analyses
of porphyrins in plasma, feces, and erythrocytes, and on FECH enzymatic
assays performed according to the European Porphyria Network (EPNET)
guidelines and quality control schemes (porphyria.eu/). Erythroid porphyrins
were measured as described previously (33). The percentage of zinc-
protoporphyrin was calculated from fluorescence emission spectra of extracted
of erythrocyte hemolysates. Porphyrins were extracted as described pre-
viously (34) and analyzed by HPLC (35). Intracellular ALA levels were mea-
sured by LC-MS/MS (UPLC-Xevo TQMS; Waters). Cells were sonicated in the
presence of 1 mM succinylacetone, and samples were pretreated by solid-
phase extraction using MCX columns (Waters). PPIX in HEK293T and MEL
cells and ALAS activity were quantified as described previously (36, 37).
Cell Culture and Metabolite Analysis. Lymphoblastoid cells were obtained
from the Biological Resource Center, Hôpital Cochin-APHP (Assistance Publique-
Hôpitaux de Paris). They were cultured in RPMI 1640 medium (Gibco)
supplemented with 10% FBS, 2% L-glutamine 200 mM, 10 mM Hepes,
and antibiotics (100 U/mL penicillin and 100 μg/mL streptomycin). CLPX
genotypes were identified by Sanger sequencing (SI Appendix, Fig. S3).
DS19 MEL clones were a gift from Arthur Skoultchi (Albert Einstein Col-
lege of Medicine), and the Biological Resource Center at Hôpital Cochin-
APHP generously established the lymphoblastoid cell lines.
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Fig. 5. CLPX and CLPXP assembly and models of the disease mechanism.
(A) Coimmunoprecipitation of purified murine CLPX variants to assess
heterooligomerization of WT and G298D variants. 3xFLAG-tagged ClpX was
immunoprecipitated from a mixture with untagged CLPX or CLPXGD. The
precipitate was separated by SDS/PAGE and stained with Sypro Orange.
(B) Pull-down to assess the interaction of CLPX variants (WT or G298D) with
CLPP-His6. 3xFLAG-tagged WT CLPX was used to distinguish it from CLPX
GD.
CLPX were incubated with CLPP-His6 and His-Tag Dynabeads in the presence
or absence of 2.5 mM ATPγS. Coisolated proteins were separated by SDS/
PAGE and stained with Sypro Red. With ATPγS, total pull-down of CLPX with
CLPP in the mixed WT and G298D CLPX sample was 0.5 ± 0.1 relative to WT
CLPX; no significant association of CLPXGD alone with CLPP was observed.
P = 0.002 (Student’s t test, n of 3) for reduced pull-down of mixed WT CLPX
and CLPXGD with CLPP. (C) Models of CLPX regulation of ALAS. (Left) Under
normal circumstances, CLPX (blue circles) degrades ALAS in complex with
CLPP (dark-blue cylinder), keeping ALA levels in check, preventing PPIX from
accumulating (10). Concurrently, CLPX activates ALAS by promoting PLP in-
corporation (9). Note that direct degradation by CLPXP of ALAS1 or ALAS2
has not been demonstrated in vitro, and the influence of CLPX on ALAS
stability could be more complex. (Middle) In a CLPXWT/GD heterozygote,
CLPXGD (red circles) heterooligomerizes with CLPX, to form a dominant in-
hibitor of the ATPase activity of the hexamer. The resultant CLPXP complex is
deficient in proteolytic activity, leading to an accumulation of ALAS that is
more severe than any deficiency in PLP incorporation. (Any defect in ALAS
activation by the heterohexameric CLPX has not been quantified, but likely
is less impaired than in ALAS degradation; see text). This combination results
in abnormally high ALAS activity and accumulation of PPIX, contributing to
EPP. (Right) When CLPX is lost, reduced activation of ALAS is phenotypically
stronger than increased ALAS protein, leading to decreased ALA production
and anemia (9).
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Mononuclear cellswere isolatedby Ficoll density-gradient centrifugation (PAA
Laboratories) from 60 mL of peripheral whole blood. CD34+ cells were purified
using immunomagnetic beads (MACS CD34+ MicroBead Kit; Miltenyi Biotec).
CD34+ cells were differentiated into erythroid cells by culture in Iscove’s Modi-
fied Dulbecco’s Medium (Gibco) supplemented with 15% BIT 9500 (Stemcell
Technologies), 2 U/mL EPO, 100 ng/mL SCF, 10 ng/mL IL-6, and 10 ng/mL IL-3
(Miltenyi Biotec), MEL (DS19 subclone) cells were differentiated by incubation in
complete DMEM supplemented with 2% DMSO for 3 d. To assess hemoglobi-
nization, o-dianisidine staining was performed as described previously (36).
Immunoprecipitation and Western Blot Analysis. Zebrafish embryos at 24 h
postfertilizationwith eGFP expressionwere lysed in groups of∼50 embryos in
RIPA buffer/protease inhibitor mixture (Roche) by dounce. The clarified
soluble lysate after centrifugation was immunoprecipitated with anti-FLAG
agarose beads (Sigma-Aldrich) for 12 h at 4 °C, after which immune complex
beads were serially washed with PBST/protease inhibitor mixture (Roche)
and eluted in boiling Laemmli loading solution. The eluted immune complex
was resolved on SDS/PAGE and visualized by Western blot analysis.
The following antibodies were used for Western blot analysis: peroxidase-
conjugated anti-FLAG M2 (Sigma-Aldrich), anti-ALAS1 (ab84962; Abcam), anti-
ALAS2 (ab184964; Abcam or rabbit anti-human ALAS2; Agios Pharmaceutical),
anti-CLPX (AP1067b; Abgent), anti-HSP60 (Santa Cruz Biotechnology), anti-ANT
(Santa Cruz Biotechnology), and anti–β-actin (Sigma-Aldrich).
CHX Block. Inhibition of translation was carried out with 100 μg/mL CHX
(Sigma-Aldrich) as described previously (11). Cells were harvested at in-
dicated times after CHX treatment. Proteins obtained from whole-cell ly-
sates (HEK293T cells) or mitochondrial fractions (MEL cells) were resolved by
SDS/PAGE. ALAS1, ALAS2, and CLPX were detected by Western blot analysis,
and protein levels were quantified using ImageJ (37).
CLPX Biochemistry.Murine CLPX variants and human CLPPHis6 were expressed
and purified as described previously (9). Bacterial expression vectors for the
CLPXGD and CLPX-3xFLAG proteins were generated by site-directed muta-
genesis and isothermal assembly, respectively, of the previously reported
CLPX expression vector. CLPX ATPase activity was monitored at 30 °C by
the decrease in absorbance at 340 nm in an NADH-coupled assay (2.5 mM
ATP, 1 mM NADH, 7.5 mM phosphoenolpyruvate, 20 U/mL lactate de-
hydrogenase, and 20 U/mL pyruvate kinase) in 25 mM Hepes pH 7.6, 100 mM
KCl, 5 mM MgCl2, and 10% glycerol.
Co-IP of purified CLPX-3xFLAG and CLPX variants was performed with
FLAGM2 antibody-conjugatedmagnetic agarose beads (Sigma-Aldrich). Here
0.25 μM CLPX-3xFLAG and 0.25 μM CLPX or CLPXGD were incubated in
25 mM Hepes pH 7.6, 100 mM KCl, 5 mM MgCl2, 10% glycerol, 0.1% Triton
X-100, 0.5 mg/mL acetylated BSA, and 1 mM DTT with 12 μL of beads in a
50-μL total volume on ice for 45 min with intermittent gentle mixing. Beads
and bound proteins were washed three times in binding buffer and eluted
on ice for 45 min with 30 μL of 1 mg/mL 3xFLAG peptide in binding buffer.
Eluted proteins were separated by SDS/PAGE, stained with Sypro Orange,
and imaged with a Typhoon FLA 9500 scanner (GE Healthcare). Coisolation
of CLPX variants with human CLPPHis6 was performed using His-Tag Dyna-
beads (Thermo Fisher Scientific) in the same buffer used for anti-FLAG co-IP,
except for the addition of 10 mM imidazole. CLPX variants were mixed to-
gether as indicated, and CLPPHis6 and ATPγS were added as indicated. The
mixtures were incubated for 10 min at room temperature. His-Tag Dyna-
beads were added in an equal volume of buffer to yield a concentration of
0.3 μM total CLPX hexamer (CLPX-3xFLAG, CLPXGD, or an equimolar mixture
of both) and 0.3 μM CLPP 14-mer in 30 μL. The mixtures were incubated for
10 min at room temperature with intermittent gentle mixing. Beads and
bound proteins were washed three times with binding buffer, then eluted
for 10 min at room temperature in 30 μL of binding buffer with 300 mM
imidazole. Eluted proteins were separated by SDS/PAGE, stained with Sypro
Red, and imaged with a Typhoon FLA 9500 scanner (GE Healthcare).
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